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INTRODUCTION 
Biochemistry and Metabolism of Prostaglandins 
In the 1930's, prostaglandins were discovered as constituents 
of semen and were found to be vasodepressor compounds. Their 
chemical structure and relationship to the essential fatty acids 
were first described by Bergstrom and Van Dorp in the early 1960's. 
Prostaglandins have been found in almost all tissues studied, in¬ 
cluding lung, kidney, ovaries, spleen, nerves, and heart (1). 
Under the influence of an enzyme complex, prostaglandin syn¬ 
thetase, the primary prostaglandins are synthesized from the pre¬ 
cursor fatty acids, dihomolinolenic acid and arachidonic acid, both 
of which are derived in animal tissue from the essential fatty acid, 
linoleic acid (2). 
The prostaglandins are 20 carbon compounds and are divided 
structurally into three major subgroups: A, E, and F. The E 
prostaglandins are characterized by 11-hydroxy and 9-keto groups. 
In contrast, the F class has a second hydroxyl group in lieu of the 
9-keto group. The prostaglandins are subdivided further by the 
number of double bonds in the aliphatic side chains. Prostaglandins 
Ep and F^ contain a single bond at the C 13:14 position, whereas 
prostaglandins E2 and F2 possess a double bond at that position 
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. 
The E-^ and F^ prostaglandins are synthesized from dihomolenolenic 
acid, while E^ and F2 prostaglandins originate from arachidonic 
acid. Prostaglandin A is a dehydration product in vivo of prosta¬ 
glandin E (Fig 1) . 
Using the pathway of arachidonic acid to prostaglandins E^ and 
F^ as a model, the synthetase enzyme first produces two highly active 
intermediates, endoperoxides and H^. These compounds are extremely 
labile and rapidly converted to 72 and E2. In addition, metabolism 
of the endoperoxides results in formation of thromboxanes and another 
endoperoxide, D2. It is believed that the thromboxane pathway parallels 
that of the primary prostaglandins and includes another enzyme complex, 
termed thromboxane synthetase. This pathway yields thromboxane A2, 
which then is converted to I^. These compounds are also short-lived, 
but very active in certain systems such as platelets (3,4). 
It appears that the precursor fatty acids are stored within 
the phospholipids of cell membranes. When stimulated, the endo¬ 
peroxides, prostaglandins, and thromboxanes are rapidly synthesized 
and probably stored within the membrane. Prostaglandins are rapidly 
inactivated by a 15-hydroxyprostaglandin dehydrogenase either at 
the site of action or by transport in the circulation to the lung, 
liver, or kidney (5-7). Arterial levels of prostaglandins E and F 
are very low, because these compounds are almost completely inactivated 
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Figure 1. 
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during a single circulation. 
The heart is capable of synthesizing and degrading prosta¬ 
glandins locally, as both the synthetase (8) and dehydrogenase (9) 
enzymes have been identified in canine left ventricle. Prosta¬ 
glandin synthesis in vascular smooth muscle (10,11), including 
coronary arteries (12,13), also has been documented. 
The full range of cellular actions of the prostaglandins is 
not known at this time. In general, the prostaglandins, especially 
of the E class, increase the level of intracellular cyclic AMP, 
probably via adenylate cyclase (14). 
General Pharmacology 
A potentially powerful means of elucidating the actions of 
these ubiquitous compounds has been inhibition of prostaglandin 
synthetase by anti-pyretic, anti-inflammatory, and analgesic agents, 
such as aspirin and indomethacin (15,16). These drugs have similar 
actions relative to the prostaglandin pathway, except for one 
intriguing difference: indomethacin blocks cardiac prostaglandin 
synthetase in vitro, while aspirin does not (8). Docosahexanoic 
acid, a fatty acid related to arachidonate, is also a potent inhib¬ 
itor of prostaglandin synthetase (Fig 2). Other fatty acids, such 
as linolenate and oleate, however, are not known to be inhibitors (15). 
One experimental anti-inflammatory agent has more specific 
inhibitory effects. This compound, benzydamine, is related struc¬ 
turally to indomethacin, with almost the same basic ring structure. 
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Figure 2. Prostaglandin pathways from stimulus, such as ischemia, 
through physiologic effects. Presumed sites of inhibition are 
noted by the crossed arrows. 
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Using an in vitro assay system, benzydamine was found to selec¬ 
tively inhibit synthesis of prostaglandin F and endoperoxide D, 
while either augmenting or not affecting prostaglandin E bio¬ 
synthesis in different doses (17). In a vascular smooth muscle 
preparation, its inhibition of thromboxane synthetase was 21/2 
times more effective by weight than that of prostaglandin synthetase. 
Of note, indomethacin's inhibition of the prostaglandin system 
was 10 times as potent as its inhibition of thromboxane synthetase (18). 
Other unrelated compounds, such as phloretin phosphate, have 
been found to antagonize the end-organ effects of the prostaglandins, 
by acting as competitive inhibitors. These agents primarily interact 
with the receptor site for the agonist, rather than with the syn¬ 
thetase enzyme (19,20). 
Actions of Exogenously Administered Prostaglandins 
In both isolated hearts and intact animals, prostaglandins E 
and A increase coronary blood flow and decrease coronary vascular 
resistance (21-26). The coronary vasodilator actions of these 
compounds are not mediated via the adrenergic or cholinergic ner¬ 
vous systems, as pretreatment with propranolol or atropine does not 
inhibit their vasodilatory effects (21,23,24). The inotropic 
actions of prostaglandins E and A have not been well defined and 
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are dependent on the species and model studied (25-27). In the 
intact animal, it is generally agreed that prostaglandin E pro¬ 
duces increased inotropy and chronotropy (Fig 3), although 
separation of primary and secondary effects is still not resolved 
fully (26,27). Some studies of prostaglandins in isolated ven¬ 
tricular myocardium have found no direct inotropic or chronotropic 
effects (25,26). When given systemically, prostaglandins E and A 
decrease arterial blood pressure profoundly by decreasing total 
peripheral vascular resistance. In contrast, prostaglandin F has 
little, if any, effect on blood pressure or coronary blood flow (23,24); 
only when given in high doses does prostaglandin F increase systemic 
arterial pressure, probably by peripheral venoconstriction (28). 
Studies in the isolated innervated rabbit heart have shown 
that prostaglandin E inhibits sympathetic and parasympathetic 
neurotransmission, mainly by decreasing release of transmitter 
from nerve endings. These findings suggest that prostaglandins 
synthesized endogenously act as physiological modulators of neuro¬ 
transmission in the heart (29). 
In experimental myocardial infarction, pharmacologic doses of 
prostaglandins have been shown to have beneficial effects. One 
study showed that prostaglandin E increased coronary blood flow to 
the ischemic area in comparison with the preinfarction state (30). 
In another study, after acute coronary occlusion in the cat, 
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Figure 3. Hemodynamic effects of intravenous prostaglandin 
(PGE) and prostaglandin F2cc (PGF) in the anesthetized dog. PGE 
caused a rapid decrease in mean left atrial pressure (MLAP) and 
mean systemic arterial pressure (MSA) and a rise in heart rate 
(HR), cardiac output (CO), and myocardial contractile force (MCF). 
In contrast PGF had minimal effects on HR, MLAP, and MCF. MSAP 
and mean pulmonary arterial pressure (MPAP) rose slightly. (From 
Nakano, reference 23). 
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administration of prostaglandin F increased survival time, decreased 
plasma creatine phosphokinase, and decreased myocardial lysosomal 
activity compared to controls (31,32). Recent reports have sug¬ 
gested that release of cardiac lysosomal hydrolases may signal 
irreversible cell death. They also have been implicated in the 
development of collateral blood flow (33). Stabilization of these 
enzymes by a locally synthesized agent, such as prostaglandin F, 
may maintain cellular viability and local perfusion. The incidence 
of significant ventricular arrhythmias was decreased by prostaglandin 
E following coronary occlusion in cats (34). In a similar study in 
monkeys, a stable derivative of prostaglandin A enhanced recovery 
from ventricular arrhythmias due to coronary occlusion (35). These 
later studies suggest a beneficial effect of prostaglandins on elec¬ 
trical stability of the ischemic myocardium. 
Physiologic Role of Endogenous Prostaglandins 
The release of prostaglandins from tissues subjected to acute 
ischemia was first documented in the canine kidney (36). Prosta¬ 
glandins have been implicated in vasomotor autoregulation in the 
kidney (37) , brain (38) , and uteroplacental bed (39). 
Prostaglandin biosynthesis and release have been demonstrated 
in the isolated perfused rabbit heart exposed to hypoxia (40), 
mechanical massage, elevated preload (41), vagal stimulation (42), 
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and adenosine triphosphate (43) or acetylcholine (42) administration. 
Ischemia and anoxia have produced varied effects on prostaglandin 
biosynthesis (43-45), whereas acidosis, hyperthermia, hypothermia, 
hyperosmolarity, and hyperkalemia all were without effect (41). 
Studies utilizing the open-chest dog have shown an increase in 
prostaglandins in coronary venous blood during postocclusive reactive 
hyperemia (46). The same finding has been reported following 
coronary occlusion in the canine heart-lung preparation (47). 
Based on these findings, it has been suggested that prostaglandins 
may play a regulatory role in the cardiac response to ischemia. 
However, not all published data support a role for prostaglandins 
in the regulation of coronary flow. One study has shown that indo- 
methacin diminishes the increase in coronary blood flow that results 
after release of coronary occlusion (48), while another has not re¬ 
produced these results (49). In one report, indomethacin pretreat¬ 
ment did not alter changes in coronary blood flow induced by changes 
in coronary perfusion pressure (50). Furthermore, in several models, 
indomethacin did not affect resting coronary blood flow (45,46). 
During a 5 hour coronary occlusion in cats, neither indomethacin 
nor acetylsalicylic acid had any effect on ST segment elevation, 
creatine phosphokinase release, or systemic hemodynamics (51). 
In contrast, aspirin pretreatment in open-chest dogs markedly 
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reduced the extent of ischemic myocardial injury (ST segment 
elevation) during acute occlusion (52). Of note, in the iso¬ 
lated heart model, neither phloretin phosphate nor indomethacin 
blocked the reactive hyperemic response following occlusion (53). 
Many of these conflicts may be traced to species differences 
or to technical factors relating to the models used. Most of 
the studies cited, which utilized inhibitors of prostaglandin 
synthesis, do not confirm that prostaglandin synthesis actually 
was blocked. 
Since platelet aggregation in the presence of thrombin also 
results in prostaglandin release, this phenomenon may also be 
relevant in the setting of coronary occlusion (54). Of interest, 
prostaglandin E-^ is a very potent inhibitor of platelet aggregation, 
while prostaglandin E2 stimulates aggregation and prostaglandin F 
is without effect. It has been known for many years that aspirin 
inhibits the second phase of platelet aggregation. More recently, 
it has been shown that aggregating platelets release large amounts 
of the short-lived endoperoxides, which are extremely potent inducers 
of aggregation and that aspirin blocks the formation of these endo¬ 
peroxides (3,54). 
In addition to the primary and intermediate prostaglandins, 
thromboxanes also have been implicated in platelet aggregation (55). 
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Furthermore, these compounds rapidly contract strips of porcine 
coronary artery (56). It was suggested that platelet aggregation 
in areas of damaged endothelium causes release of thromboxane 
and results in constriction of large coronary arteries. Prosta¬ 
glandins and thromboxanes have opposite effects when studied in 
isolated coronary artery muscle strips (12,13). While prostaglandins 
and F2 constrict these strips, their precursor, arachidonic acid, 
causes relaxation (12,57). The arachidonate-induced coronary relax¬ 
ation was blocked by indomethacin and aspirin. Addition of indo- 
methacin to the strips previously relaxed by arachidonate caused 
contraction. The fatty acids, linoleate and oleate, also caused 
relaxation both before and after indomethacin, thereby eliminating 
a direct non-specific effect of fatty acids as the cause of arach¬ 
idonate-induced relaxation. These results suggest that arachidonic 
acid undergoes conversion within coronary vascular muscle to an endo¬ 
genous dilating compound, which may be a thromboxane (12). It is 
puzzling to note that in this in vitro model, prostaglandin E causes 
smooth muscle contraction, while ini vivo, it is a potent vasodilator, 
suggesting muscular relaxation. 
Many investigators have hypothesized potentially beneficial 
effects for aspirin in myocardial infarction or ischemia. These 
have been based primarily on inhibition of the second phase of 
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platelet aggregation (58). The clinical and experimental reports 
are conflicting. Aspirin (30 mg/kg, iv) has produced a favorable 
effect during coronary occlusion in the open-chest dog, manifested 
by a decrease in epicardial ST segment elevation (52). In a ran¬ 
domized controlled trial, chronic aspirin therapy was ineffective 
in reducing reinfarction in patients who had experienced an earlier 
myocardial infarction (59). However, the Boston Collaborative Drug 
Surveillance Group reported a negative association between aspirin 
intake and subsequent non-fatal myocardial infarction, suggesting 
that aspirin protects against this disease (60). One study that 
evaluated aspirin in patients with angina pectoris found that 
this drug did not affect exercise tolerance or ischemic electro¬ 
cardiographic changes (61). The controversy is unresolved at this 
time. 
Myocardial Intermediary Metabolism 
The myocardial cell generates virtually all its energy by oxi¬ 
dative phosphorylation within the mitochondria, uses almost any sub¬ 
strate as fuel for this process, and functions essentially by aerobic 
processes under normal conditions. This is attested to by the large 
number of mitochondria within the myocardial cell and the extremely 
rich concentration of oxidative and respiratory chain enzymes. 
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Free fatty acids are decarboxylated, and glucose passes 
down the Embden-Meyerhof pathway until it is transformed into 
pyruvate. Each two-carbon fragment is transferred with acetyl co¬ 
enzyme A from the cytoplasm to the mitochondrion where these 
components enter into the tricarboxylic acid cycle (Fig 4A). They 
they are broken down into smaller units with the progressive release 
of electron energy. As energy is released and captured within the 
various flavoproteins and oxidases, carbon dioxide is generated and 
high-energy phosphate compounds are synthesized, the compound rich¬ 
est in energy being adenosine triphosphate. Under ordinary conditions, 
this high-energy phosphate is available for the performance of cell¬ 
ular work at the membrane pumping sites, at the contractile proteins, 
or in cell synthesis (62,63). 
This cycle is interrupted, however, whenever there is in¬ 
sufficient oxygen to join with free hydrogen at the end of the 
hydrogen accepter chain in the final formation of water (Fig 4B). 
During ischemia, when oxygen availability is limited, this causes 
a reduction in the chemical state of each of the constituents of 
the mitochondrial respiratory chain. When these moieties exist 
in reduced forms, the Krebs cycle slows down and hydrogen is trans¬ 
ferred from the mitochondrion to the cytoplasm. The later phenom¬ 
enon occurs by means of a hydrogen shuttle, presumably utilizing 
-14- 

Figure 4. Myocardial intermediary metabolism. 
4A (Upper): Normal pathways. 
4B (Lower): Modified pathways during ischemia. 
Note the production of lactate from pyruvate and its diffusion 
into the extracellular space. The thickness of arrows represents 
relative changes. (From Scheuer, reference 62). 
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the amino acid carnitine as the intermediate substance. As a 
result of this shuttle, the NAD of the cytoplasm becomes as reduced 
as the NAD of the mitochondrion. As soon as there is sufficient 
NADH in the cytoplasm, this shifts the redox potential of the lactate- 
pyruvate reaction. 
Under normal conditions, pyruvate couples with acetyl coenzyme 
A to enter the mitochondrial energy cycle. Now, however, in the 
presence of NADH, pyruvate acts as a hydrogen acceptor and 
becomes lactate. Thus, pyruvate is shunted away from the mitochondria, 
and cytoplasmic lactic acid is generated. This lactic acid accumulates 
within the cell in a concentraion many times greater than that in 
the plasma and eventually appears within extracellular fluid and 
finally in the coronary capillaries and venous circulation (62,63). 
Prostaglandin Substrates 
The relationship of prostaglandins and free fatty acids is 
intriguing (2). It has been shown in the past that elevation of 
plasma concentrations of free fatty acids increases myocardial 
oxygen consumption, depresses regional myocardial contractility, 
and increases the incidence of arrhythmias (64,65). 
Fatty acids are important fuels for myocardial cells, and 
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prostaglandins are known to stimulate fatty acid uptake in iso¬ 
lated hearts. It is not known whether the type of free fatty acid 
reaching the heart determines its function or influences the degree 
and direction of prostaglandin synthesis. If common free fatty acids 
act as less effective substrates for prostaglandin synthetase and 
thus inhibit the system, this may explain some of the deleterious 
effects reported for free fatty acids in the setting of myocardial 
ischemia (15,16). 
The fatty acids that serve as precursors for prostaglandin 
synthesis are released from membrane phospholipids. These phospho¬ 
lipids also contain fatty acid derivatives that may act as inhibitors 
of prostaglandin synthesis, and these inhibitors may be released with 
the necessary precursor fatty acids (2). Prostaglandin biosynthesis 
and control of cellular lipolysis thus may be interrelated and depend 
on fatty acid composition of membrane phospholipids. For example, 
while arachidonic acid is a precursor of prostaglandin E0, a struc¬ 
turally similar fatty acid, docosahexanoic acid, is a potent inhibitor. 
This is most probably accomplished by competitive binding at the sub¬ 
strate site of the oxygenase (synthetase) (15). In the dog, infusion 
of arachidonic acid results in an increase in total coronary blood 
flow. The investigators hypothesized that this was due to synthesis 
of vasodilatory prostaglandins. The increase in flow was blocked 
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by pretreatment with indomethacin (66) . Arachidonic acid also 
has been shown to contract isolated smooth muscle strips, an 
effect blocked by indomethacin (57). Further confirmation of 
such pathways in vivo is still required. 
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MATERIALS AND METHODS 
Studies I and II; Cardiac Prostaglandin Release During Coronary 
Occlusion in Closed-Chest Dogs 
Initial experiments (I) were designed to determine if prosta¬ 
glandins are released from the heart following coronary occlusion; 
which prostaglandins are released; and the time course of release. 
Subsequent experiments (II) investigated the site of prostaglandin 
release by selective sampling of venous drainage from ischemic and 
non-ischemic myocardial regions. 
I. Seven healthy closed-chest mongrel dogs, weighing 20-31 kg, 
were anesthetized with sodium pentobarbital (35 mg/kg, iv) and 
ventilated mechanically with room air by a Harvard respirator. All 
animals received 3000 U heparin iv. BlPod volume removed for sam¬ 
pling was replaced simultaneously by normal saline. 
A no 7 French Sones catheter was positioned fluoroscopically 
approximately 2 cm beyond the orifice of the coronary sinus. Aortic 
pressure was measured by a Statham P23DB transducer connected through 
a fluid-filled system to a catheter placed in the descending aorta. 
The lead electrocardiogram was monitored continuously. Pressure 
and electrocardiogram were recorded on a DP-12 Electronics for Medicine 
multi-channel recorder. 
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Baseline aortic and coronary sinus blood samples (7 ml each) 
were drawn simultaneously. A balloon-tipped catheter was then 
positioned under fluoroscopic control in the proximal left anterior 
descending coronary artery. This placement was confirmed by injec¬ 
tion of contrast medium (sodium meglumine and diatrizoate). The 
balloon then was inflated, completely occluding the left anterior 
descending coronary artery (Fig 5). ST segment elevation consis¬ 
tent with ischemia was noted immediately in all animals. Following 
occlusion, and at 5 to 10 min intervals thereafter, blood samples 
were drawn from the aorta and coronary sinus (7 ml each) into 
plastic syringes. Sampling times following occlusion differed in 
individual animals because of variation in the animals’ hemodynamic 
and electrical responses to ischemia. Experiments were continued 
until death from ventricular arrhythmias or up to 3 hours in 
surviving animals. 
Following occlusion, arterial pressure decreased by about 20% 
in every animal. None went into shock unless ventricular tachycardia 
or fibrillation occurred. 
In 2 control animals, the identical protocol was carried out 
without inducing coronary occlusion. Samples were obtained from 
similar sites at 15 min intervals for a total of 90 min. 
II. Six closed-chest dogs (22-29 kg), anesthetized with sodium 
-20- 

BALLOON TIPPED 
CATHETER IN 
Figure 5. Experimental preparation used in Study I. Sampling 
catheters are in the coronary sinus and aorta. The inflated 
balloon tipped catheter is located in the left anterior descending 
(LAD) coronary artery. 
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pentobarbital (35 mg/kg, iv) were studied. A no 7 French Sones 
catheter was positioned fluoroscopically in the proximal coronary- 
sinus 2 cm beyond the orifice; another was passed more distally 
into the great cardiac vein as far anteriorly as possible. Aortic 
pressures and electrocardiogram were monitored as previously des¬ 
cribed. A balloon-tipped catheter was placed under fluoroscopic 
control into the left circumflex coronary artery (Fig 6). Its 
position was confirmed by injection of contrast medium. Baseline 
samples from the aorta, coronary sinus, and great cardiac vein 
were obtained before inflation of the balloon and then at 5 to 10 
min intervals thereafter. 
The great cardiac vein receives anterior drainage from the 
area perfused by the left anterior descending artery, while both 
the anterior great cardiac vein effluent and the posterior drainage 
from the left circumflex distribution reach the coronary sinus (67). 
Therefore, during left circumflex occlusion, great cardiac vein 
effluent would be from normal (non-ischemic) myocardium, whereas 
coronary sinus drainage would necessarily include blood from 
ischemic and non-ischemic regions. Such sampling allows analysis 
of regional prostaglandin release. 
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Figure 6. Experimental preparation used in Study II. The 
inflated balloon tipped catheter is in the left circumflex (LCF) 
coronary artery. Catheters in the great cardiac vein and coronary 
sinus are used for sampling from the non-ischemic and ischemic 
zones, respectively. 
BALLOON 
OCCLUSION 
CATHETER 
IN GREAT 
CARDIAC 
VEIN 
CATHETER IN 
CORONARY 
SINUS 
BALLOON TIPPED 
CATHETER IN LCF 
CATHETER 
IN AORTA 
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Data Analysis 
The first sample obtained immediately after occlusion never 
showed any arterio-venous prostaglandin difference. This sample, 
therefore, was not included in analysis in any experiment. All 
subsequent post-occlusion samples were analyzed by several approaches. 
Firstly, each animal was treated as a separate, independent exper¬ 
iment in which paired aorta and coronary sinus, aorta and great 
cardiac vein, or coronary sinus and great cardiac vein samples were 
compared by a paired t test. In addition, for each of the three 
sampling sites, the mean + SE post-occlusion value was calculated 
for each animal. Secondly, individual animals were grouped to 
assess the overall response. Because the number of samples obtained 
after occlusion differed in individual studies, the group means for 
each sampling site were determined from weighted means of each 
animal's prostaglandin level; the weighting factor used was the 
inverse of the individual variances (68). Paired, weighted aorta 
and coronary sinus, aorta and great cardiac vein, or coronary sinus 
and great cardiac vein samples were compared by a t test. 
Analysis of prostaglandin levels at baseline before occlusion 
and at the time of maximal prostaglandin release after occlusion 
was also undertaken. At each of these sampling times, arterial and 
venous values were compared by a paired t test. Mean + SE arterio-venous 
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differences at these times were also determined. 
Probability (P) less than 0.05 was considered significant. 
Study III: Cardiac Prostaglandin Release During Atrial Pacing 
in Patients with Coronary Artery Disease 
This study was designed to document the presence or absence 
of prostaglandin release from the human heart during varifiable 
myocardial ischemia in patients with coronary artery disease. 
Atrial pacing for evaluation of myocardial lactate metabolism 
during ischemia is routinely performed during diagnostic cardiac 
catheterization in this laboratory. This protocol was approved 
by the Yale University School of Medicine Human Investigation 
Committee, and all patients gave informed consent for participation. 
Twelve patients were selected for inclusion in the study. The 
selection criteria were established to document the presence of 
myocardial ischemia during pacing. All twelve patients had multi¬ 
vessel coronary artery disease documented by angiography, with 
significant narrowing (greater than 75%) of luminal diameter of at 
least two major vessels. During atrial pacing, they all developed 
characteristic anginal symptoms, associated with electrocardiographic 
changes consistent with myocardial ischemia (1 mm flat or downsloping 
ST segment depression, 0.08 mm in duration in at least 3 consecutive 
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beats). All patients demonstrated lactate production or a marked 
decrease from resting lactate extraction, suggesting a shift to 
anaerobic metabolism. 
Ten patients were male and 2 female. Their mean age was 52 
years, mean (+ SE) resting supine blood pressure 134/86+6/4. Four 
had a history of myocardial infarction. Five were receiving pro¬ 
pranolol. Mean peak pacing rate achieved was 134 beats/min (range 
90-150). 
Three additional patients, evaluated for a chest pain syndrome, 
proved to have completely normal coronary arteriographic studies. 
Atrial pacing in these patients achieved a maximal heart rate 
equivalent to that in the experimental group (mean 150 beats/min, 
range 140-160). While these subjects did experience mild chest 
pain, none demonstrated lactate production or electrocardiographic 
changes. These patients, therefore, constituted a control population. 
Two were male and one female. Average age was 47 years, mean resting 
supine blood pressure 135/80. None had experienced myocardial infarction, 
and none were receiving propranolol. 
Two of the patients with coronary disease (nos 9 and 10) also 
were considered controls, because blood samples drawn at heart rates 
prior to the onset of angina or electrocardiographic changes were 
assayed for prostaglandins. 
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Pacing Protocol 
All patients were premedicated with diazepam (10 mg, po) 
before being brought to the catheterization laboratory. A no 
7 French Zucker pacing catheter was positioned fluoroscopically 
2 cm beyond the orifice of the coronary sinus. Position was 
confirmed by injection of contrast medium (sodium meglumine and 
diatrizoate). This catheter was used for coronary sinus sampling 
and atrial pacing. A no 7 NIH angiography catheter was placed in 
the ascending aorta for sampling and pressure recording connected 
through a fluid-filled system to a Statham P23DB transducer (Fig 7) 
The lead electrocardiograph was monitored throughout and 
recorded with the pressure on an Electronics for Medicine DR8 
multichannel recorder. 
Atropine (0.5 mg, iv) was infused in all patients to prevent 
atrioventricular block. Pacing then was begun at a rate of 10 
beats/min greater than control and usually increased in increments 
of 10 beats/min each successive min. The end-point for termination 
of pacing was chest pain described by each patient as similar to 
his usual anginal symptoms. Angiographic study followed thereafter 
Blood samples were drawn simultaneously from coronary sinus 
and aorta at rest, during peak pacing (angina), and five min after 
termination of pacing (recovery). Two ml samples were drawn for 
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Figure 7. Angiographic study seen in Study III. Contrast 
medium is injected in the coronary sinus to confirm the position 
of the catheter. The left ventricular catheter often is pulled 
back to the aortic arch. 
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lactate determination and 10 ml samples for prostaglandin assay; 
the order of sampling for lactate and prostaglandin was random¬ 
ized. Immediately after withdrawal into plastic syringes, blood 
samples for prostaglandin analysis were transferred to heparin¬ 
ized tubes which were capped and stored on ice until completion 
of the catheterization procedure. Lactate samples were immed¬ 
iately transferred into iced perchloric acid for deproteinization 
and stored on ice. 
After deproteinization, samples were centrifuged at 1000 g 
for 10 min. The plasma was decanted and frozen. Lactate was 
assayed enzymatically using the Boehringer-Mannheim assay kit; 
spectrophotometric measurements were made at 366 nm (69). All 
samples were assayed in duplicate; results are reported as the 
mean of the values. The inter-assay variation was less than 10%. 
The data are expressed as lactate uptake (%): 100’(AO-CS)/AO, 
where AO = aortic lactate concentration and CS = coronary sinus 
lactate concentration. Markedly decreased lactate extraction 
(positive value) or lactate production (negative value) is con¬ 
sidered abnormal and has been correlated with regional myocardial 
ischemia (70,71) (Fig 4). 
-29- 

Statistical Methods 
Prostaglandin levels were expressed as the mean + SE for aortic and 
coronary sinus samples. The paired t test was used to analyze 
differences between aortic and coronary sinus values at rest, 
during angina, and after recovery. Independent groups were compared 
ty Student’s t test. Probability (P) less than 0.05 was taken as 
a significant difference. 
Radioimmunoassay of Prostaglandins 
Tubes containing blood for prostaglandin assay were centrifuged 
at 1000 for 10 min. The plasma was decanted into scintillation 
vials which were sealed and stored in a freezer at -20°C. Hemo- 
lyzed samples were discarded; extreme care was taken to remove 
only plasma in the supernatant, leaving behind all formed blood 
elements including platelets. Assays were completed within two 
weeks of each pacing study. 
Plasma samples were assayed for prostaglandins F, E, and A 
by radioimmunoassay, as standardized in this laboratory (72). Two 
ml plasma samples were acidified mildly with 0.1 N hydrochloric 
acid and extracted twice with 7 ml ethyl acetate. Silicic acid 
column chromatography was used to separate the three major groups 
of prostaglandins. Values are expressed as major groups, since 
the chromatography is unable to differentiate sub-groups (i.e.. 
-30- 

prostaglandins E- and E2). Varying concentrations of methanol 
in benzene and ethyl acetate were used for elution. Antibodies 
were generated in rabbits by immunization utilizing prostaglandin 
bound to bovine serum albumin; the full characterization of the 
antibodies used in this study has been reported previously (72,73). 
Charcoal-coated dextran in buffer was used to separate bound and 
unbound prostaglandin. All assays had at least 65% recovery 
efficiency. The inter-assay and intra-assay variation was less 
than 15%. All samples were run in duplicate, but in different 
sample sized; results are reported as corrected means of the two 
values. The lower limit of sensitivity of the assay is approxi¬ 
mately 0.1 ng/ml. 
Study IV: Effect of Indomethacin During Coronary Occlusion 
In Open-Chest Dogs 
Experiments were designed to evaluate the effects of inhibi¬ 
tion of prostaglandin synthesis by indomethacin on myocardial ischemia.* 
Nineteen healthy dogs, weighing 20-41 kg, were anesthetized with 
Dial-urethane (Allobarbital, 60 mg/kg; urethane, 240 mg/kg, and mono- 
ethylurea, 240 mg/kg) and ventilated mechanically on room air. 
* This study was carried out in association with Ralph Kirmser, M.D. 
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A left thoracotomy was performed in the fourth left intercostal 
space, and the heart was suspended in a pericardial cradle. The 
left anterior descending coronary artery was dissected free 
approximately 2-3 cm from its origin and isolated with a snare 
for subsequent occlusion. A short double-lumen catheter was 
placed in the left atrium, and catheters inserted into the right 
and left femoral arteries and right femoral vein. All animals 
received 2000 U heparin iv. The lead II electrocardiogram was 
monitored continuously. Pressure and electrocardiogram were 
recorded on a DR-12 Electronics for Medicine multichannel recorder. 
The left anterior descending coronary artery was then occluded. 
At 35 min after occlusion, 10 dogs received indomethacin (10 mg/kg, iv); 
9 dogs received only saline, the indomethacin vehicle. 
Epicardial ST segment mapping was performed according to the 
method described by Maroko and co-workers (74). A saline-soaked, 
cotton wick electrocardiographic probe was applied lightly to approx¬ 
imately 18 sites on the anterior surface of the left ventricle. 
These sites were distributed in areas supplied by the occluded 
artery, as well as areas remote from it and presumably adequately 
perfused. Epicardial electrograms, obtained at a sensitivity of 
1 millivolt per mm amplitude, were obtained 5 min prior to 
occlusion of the left anterior descending coronary artery and every 
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5 min after occlusion for 80 minutes. ST segment elevation was 
measured at 100 milliseconds after the onset of the QRS complex. 
Any site which exhibited a QRS exceeding 65 milliseconds in 
duration on any single tracing was excluded from analysis for 
the entire experiment, thus eliminating sites manifesting conduction 
defects. The average ST segment elevation and the number of sites 
with ST segment elevation exceeding 2 millivolts were determined 
at 30, 60 and 75 min. 
Regional myocardial blood flow was obtained at 30, 60 and 75 
min following coronary artery occlusion using 15 micron carbonized 
microspheres, labelled with cerium-141, strontium-85, and chromium-51. 
Immediately before use, the microspheres were thoroughly agitated 
for 10 min. Approximately 1.5 to 2 million microspheres were 
injected into the left atrium for each measurement. Arterial ref¬ 
erence blood samples were withdrawn from the femoral artery at 
15 ml/min for 2 min using a Harvard pump. This also was performed 
at 30, 60 and 75 min after occlusion. 
At 85 min, the heart was excised rapidly. Epicardial fat, 
vessels, and connective tissue and endocardial connective tissue were 
dissected away meticulously. Multiple 1 to 2 g biopsies were obtained 
from the distribution of the left anterior descending coronary artery. 
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In addition, four biopsies also were taken from the distribution 
of the left circumflex coronary artery. These biopsies were 
weighed and counted. 
The radioactivity in the myocardial biopsies and in the 
reference blood samples due to each of the three gamma emitting 
radionuclides was measured in a well-type sodium iodide scin¬ 
tillation counter using differential spectrometry. Regional 
myocardial blood flow (ml/100 g/min) was calculated using the 
following formula: MBF=(C x RBF/C-) x 100, where MBF equals 
regional myocardial blood flow, Cg equals counts/g in the biopsy, 
RBF equals the reference blood flow (15 ml/min), and C equals 
R 
total counts in the reference blood sample. Biopsies with myo¬ 
cardial blood flow less than 30 ml/100 g/min at 30 min were 
pooled for each dog and defined a zone of severe ischemia. 
Those biopsies with flows between 30 and 60 mg/100 g/min at 30 min 
also were pooled for each dog and defined a zone of moderate 
ischemia. The biopsies from the distribution of the left circumflex 
coronary artery defined the non-ischemic zone for each dog. 
Regional myocardial blood flow was also determined in this zone 
at 30 min. 
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Statistical Methods 
Data from animals treated with indomethacin were compared 
to those treated with saline at 30, 60, and 75 min after occlusion 
by unpaired t-test. Because each determination of myocardial 
blood flow in the moderately and severely ischemic zones was based 
on a different number of biopsies, the group means were weighted 
by the number of samples (68). 
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RESULTS 
Study I 
All 7 animals demonstrated release of prostaglandin F after 
occlusion (Table 1). Mean post-occlusion aortic levels were 0.26 
+0.1 ng/ml, while coronary sinus were 0.67 + 0.1 ng/ml (p < 0.001). 
Three of these animals showed greater than 1 ng/ml prostaglandin F 
release. 
In 6 of 7 experiments, coronary sinus levels of prostaglandin 
E were significantly greater than aortic after occlusion. Aortic 
prostaglandin E averaged 0.24 + 0.01 ng/ml, while coronary sinus 
was 0.44 + 0.01 ng/ml (p < 0.001) after occlusion. 
There were no significant post-occlusion differences between 
aorta and coronary sinus prostaglandin A in any individual animal 
or for the group of animals (p > 0.05). 
Before coronary occlusion (baseline), there were no significant 
arterio-venous differences (Fig 8). After occlusion, maximal re¬ 
lease of prostaglandin E averaged 0.76 + 0.23 ng/ml. Maximal pros¬ 
taglandin F averaged 0.91 + 0.33 ng/ml. 
In the 2 control experiments, there was no detectable release 
of prostaglandin due to experimental manipulations or blood with¬ 
drawal (Table 2). 
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PGA PGE PGF 
Figure 8. Mean aorta-coronary sinus prostaglandin differences 
at baseline and at time of maximal prostaglandin release following 
left anterior descending coronary artery occlusion in 7 dogs. 
Negative values indicate cardiac prostaglandin release. Vertical 
bars represent standard errors. Statistical significance of 
coronary sinus prostaglandin levels compared to aortic levels was 
determined by a paired t test. NS = Not significant. 
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Release of prostaglandin E or prostaglandin F occurred 
within 10 min of occlusion in all animals. Once present, prosta¬ 
glandin release was maintained until the animal died or until 
the experiment was terminated. Prostaglandin release was greater 
in magnitude, and appeared earlier, in those animals surviving 
less than 20 min. 
Study II 
Plasma prostaglandin E and prostaglandin F levels, measured 
for a representative experiment, are shown in Figs 9 and 10. 
Aortic prostaglandin E remained constant following occlusion, 
while both coronary sinus (ischemic drainage) and great cardiac 
vein (non-ischemic drainage) prostaglandin E concentrations x^ere 
elevated significantly. Aortic prostaglandin F also remained 
constant throughout the experiment. Proximal coronary sinus drainage, 
predominantly representing the ischemic region, contained elevated 
prostaglandin F levels immediately after occlusion and throughout 
the study. However, there was no release of prostaglandin F from 
the normal zone drained by the distal great cardiac vein. There was 
no prostaglandin A release from either site. 
Five of 6 animals demonstrated significant release of prosta¬ 
glandin E from the great cardiac vein drainage, and all 6 showed 
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Figure 9. Prostaglandin E levels before and after left circumflex 
coronary artery occlusion in a representative dog (II) . The 
animal died from ventricular arrhythmias about 65 minutes after 
occlusion. 
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Figure 10. Prostaglandin F levels before and after left 
circumflex coronary artery occlusion in the same dog as in 
Figure 9. 
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release from the coronary sinus (Table 3). Mean aortic prosta¬ 
glandin E was 0.21 + 0.01 ng/ml. Mean great cardiac vein was 
0.55 + 0.02 ng/mi (p < 0.001), and mean coronary sinus prosta¬ 
glandin E, 1.07 + 0.04 ng/ml (p < 0.001, compared with aortic 
levels). 
All 6 animals demonstrated release of prostaglandin F from 
the ischemic region (proximal coronary sinus), while only one 
animal showed release from the non-ischemic region (distal great 
cardiac vein). Mean aortic prostaglandin F was 0.32 + 0.01 ng/ml 
(p < 0.05). Coronary sinus prostaglandin F was significantly 
elevated at 1.69 + 0.03 ng/ml (p < 0.001). 
There was no significant release of prostaglandin A in any 
of the individual animals following coronary occlusion. However, 
there was a small, but statistically significant increase in mean 
great cardiac vein prostaglandin A. Relative to the sensitivity 
of the assay, this difference (0.03 ng/ml) is too small to be 
meaningful. 
When arterio-venous differences for prostaglandin were 
analyzed, no significant difference was noted prior to occlusion. 
The aorto-venous differences at the time of maximal prostaglandin 
release post-occlusion are shown in Fig 11. Prostaglandin F 
was released only from the ischemic zone, with a maximal aorto-venous 
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Figure 11. Mean aorto-venous prostaglandin differences at time 
of maximal prostaglandin release following left circumflex 
coronary artery occlusion in 6 dogs (II) . Negative values 
indicate cardiac prostaglandin release. Vertical bars represent 
standard errors. Statistical significance of coronary sinus (CS) 
or great cardiac vein (GCV) prostaglandin levels compared to 
aortic levels was determined by a paired t test. 
The venous sampling sites were similarly compared. 
NS = Not significant. 
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difference of -1=39 + 0.15 ng/ml. In contrast, prostaglandin E 
was released from both ischemic and non-ischemic regions, -1.09 
+0.09 and -0.52 + 0.04 ng/ml, respectively. 
Study III 
At rest, prior to pacing, there was no difference discernible 
between aortic and coronary sinus prostaglandin F levels (p > 0.05) 
During angina, ST segment changes, and lactate production (or 
markedly decreased extraction) suggesting myocardial ischemia, 
there was significant release of prostaglandin F. A myocardial 
aorto-venous difference of -0.30 + 0.04 ng/ml (p < 0.001) was found 
At recovery, coronary sinus prostaglandin F was still elevated 
above aortic levels. Throughout the pacing study, aortic levels 
were constant (Fig 12). 
The release of prostaglandin F occurred in 11 of 12 patients 
(Fig 13). The response of the 5 patients receiving propranolol 
was indistinguishable from that of the patients who did not receive 
propranolol (p > 0.05). The one patient (no 4) who did not demon¬ 
strate prostaglandin F release was indistinguishable from the 
other patients by clinical or angiographic criteria. None of the 
3 control patients with normal coronary anatomy manifested prosta¬ 
glandin release. 
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Figure 12. Plasma prostaglandin F levels in 12 patients with 
coronary artery disease. "Recovery" was 5 minutes after con¬ 
clusion of pacing. Statistical significance was determined by 
a paired t test. NS = Not significant. 
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Aorta Coronary 
Sinus 
(at angina) 
Figure 13. Plasma prostaglandin F levels at peak pacing rate 
achieved in 12 patients with coronary artery disease and in 3 patients 
with normal coronaries. All patients in the first group had typical 
anginal pain, electrocardiographic changes consistent with ischemia, 
and myocardial lactate production at peak pacing rate, while control 
patients only had mild chest pain. Mean prostaglandin F for the 
group of 12 patients is shown by the circled bar on either side of 
the panels; vertical bars represent standard errors. Statistical 
significance refers to paired comparison of aortic and coronary sinus 
prostglandin F levels in the group of 12 patients. CAD^Coronary artery disease. 

In the study group, the mean lactate uptake was -10.2%, 
indicative of myocardial lactate production, while in the control 
group, mean lactate uptake was +25.4%. Although there is 
an association between lactate production (or markedly decreased 
extraction) and myocardial prostaglandin F release in patients 
with multivessel coronary artery disease, a quantitative 
correlation between these 2 biochemical parameters could not be 
established (Table 4). At angina, 7 of the patients with coronary 
disease had profound production of lactate, ranging from -10% to -26% 
uptake. Five had either moderate production or diminished extraction. 
The mean prostaglandin F release in these 2 groups was not different 
(p < 0.05). In addition, there was no relationship between the 
magnitude of prostaglandin F release and the extent or distribution 
of coronary arterial lesions, the depth of ST segment depression, 
or the maximal heart rate achieved on pacing. 
Two patients were studied at heart rates preceding the devel¬ 
opment of angina (Fig 14). Aortic prostaglandin F levels were con¬ 
stant at all pacing rates. Neither patient demonstrated prosta¬ 
glandin F release at rest. Patient 9 had no release at rates of 
70 or 80 beats/min, but did manifest prostaglandin F release when 
angina and ST segment depression developed (heart rate 90). Similarly, 
patient 10 showed prostaglandin F release only at a rate producing 
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Figure 14. Plasma 
atrial pacing in 2 
prostaglandin F at 
prostaglandin F levels at rest and during 
patients. There was no cardiac release of 
sub-anginal heart rates. 
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angina (120 beats/min), but not at 70, 80 or 100 beats/min. 
Prostaglandin E release was not observed at rest or recovery. 
At the time of angina, there was a small, but statistically sig¬ 
nificant aorto-venous difference. Although this -0.10 + 0.03 
ng/ml difference is statistically significant, it is at the lower 
limit of sensitivity of the radioimmunoassay technique used 
(0.10 ng/ml), and therefore cannot be the basis for definitive 
conclusions. The trend shown (Fig 15) is similar to that for 
prostaglandin F, yet only 6 of the 12 patients had aorto-coronary 
sinus differences greater than -0.10 ng/ml. Prostaglandin A 
release was not observed at rest, during angina, or after recovery 
(Fig 16) . 
Study IV 
The experiments in 9 control animals demonstrated an immediate 
increase in ST segment elevation following occlusion. Both the 
average ST segment elevation and the number of sites with greater 
than 2 mm elevation rose progressively during the first 30 min, but 
remained stable from 30 min through the end of the observation 
period. Myocardial blood flow measurements in control animals were 
unchanged at 30, 60, and 75 min in each of the 3 zones. 
Indomethacin did not affect heart rate, mean arterial blood pressure, 
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Figure 15. Plasma prostaglandin E levels in 12 patients with 
coronary artery disease. Although statistically significant, 
the aorta-coronary sinus difference at angina is too small an 
absolute difference on which to base conclusions (See text). 
NS = Not significant. 
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Figure 16. Plasma prostaglandin A levels in 12 patients with 
coronary artery disease. There was no release of prostaglandin 
A at any time. NS = Not significant. 
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or their product. At 60 min, the double product averaged 22.6 + 
0.5 mm Hg x beats x min x 10 for the control group and 22.1 + 
0.4 for the indomethacin group (p > 0.05). Myocardial blood flow 
in the normal zone was not altered by indomethacin (control, 126 + 
12 ml/100 g/rain; indomethacin, 122 + 14; at 60 min, p > 0.05). 
These data suggest that myocardial oxygen demand remained constant 
during the course of each study. 
However, in comparison to control animals, those treated with 
indomethacin manifested a significant increase in both the average 
ST segment elevation (Fig 17) and the number of epicardial sites 
with at least 2 mm elevation (Fig 18). At 60 min after occlusion, 
which is 25 min after indomethacin administration, average ST 
segment elevation was 4.9 + 1.1 mm (compared to control, 1.4 + 
0.6; p < 0.025) and number of sites was 10.3 + 1.1 (compared to 
control, 3.9 + 1.2; p < 0.001). Furthermore, myocardial blood 
flow in the moderately and severely ischemic zones was diminished 
at 60 and 75 min in the animals given indomethacin (p < 0.05) 
(Figs 19,20). 
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Figure 17. Average ST segment elevation (EST) in 10 dogs given 
indomethacin and 9 given saline (control). Indomethacin, admini¬ 
stered 35 minutes (min) after occlusion, caused a significant 
increase in EST at 60 and 75 min. Vertical bars represent 
standard errors. Statistical significance was determined by 
unpaired t test. NS = Not significant. 
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Figure 18. Number of epicardial sites with ST segment greater than 
2 mm (NST) in 10 dogs given indomethacin and 9 given saline (Control). 
Indomethacin caused a significant increase in NST at 60 and 75 minutes 
(min) after occlusion. NS = Not significant. 
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Figure 19. Myocardial blood flow (MBF) in the zone of moderate 
ischemia. In the 10 dogs given indomethacin, MBF was significantly 
less at 60 and 75 minutes (min) after occlusion than in the 9 given 
saline (control). Statistical significance was determined by 
unpaired t test. NS = Not significant. 
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Figure 20. Myocardial blood flow (MBF) in the zone of severe 
ischemia. In the 10 dogs given indomethacin, MBF was signif¬ 
icantly less at 60 and 75 minutes (min) after occlusion than in 
9 given saline (control). NS = Not significant. 
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DISCUSSION 
Studies I and II demonstrate the release of prostaglandin E 
and prostaglandin F from the canine heart during myocardial is¬ 
chemia. This finding in the intact anesthetized dog is in agree¬ 
ment with earlier studies using the perfused rabbit heart (40-45) 
and the work by Alexander e_t ajL (46) using the canine heart-lung 
preparation. In contrast to the data of Kraemer ert elL (47) , 
release of prostaglandin A was not shown at any time. The validity 
of prostaglandin A values in the dog may be questioned because of 
the presence in canine plasma of a prostaglandin A isomerase, which 
converts prostaglandin A to prostaglandin B (75). 
The release of both prostaglandin E and prostaglandin F from 
the heart during ischemia resembles the findings of McGiff et_ aL (36) 
in the kidney. During canine renal ischemia, prostaglandin E and 
prostaglandin F were identified in renal vein blood by bioassay 
and thin layer chromatography. Recent studies from that group (76) 
have demonstrated the enzymatic conversion of prostaglandin E to 
prostaglandin F in the rabbit kidney, suggesting that some of the 
prostaglandin F measured may have been released as prostaglandin E. 
Similar conversion might also occur in the heart. 
Prostaglandin E was found in the venous effluent from both 
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ischemic and non-ischemic regions, while prostaglandin F release 
was limited to the ischemic region. These findings suggest that 
the roles of prostaglandin E and prostaglandin F may be different. 
Several earlier studies have demonstrated different physiologic 
effects for these two prostaglandins in the cardiovascular system. 
Prostaglandin E (but not prostaglandin F) increases myocardial adenyl 
cyclase (14), increases vascular Na+ - K+ - ATPase (77) , and inhibits 
adrenergic transmission by post-junctional depression (29). On the 
other hand, prostaglandin F in low doses (but not prostaglandin E) 
acts at the cardioregulatory and vasomotor centers of the hind brain 
to regulate vagal tone to the heart (78). 
The release of prostaglandin F from the human heart during 
myocardial ischemia was demonstrated in study III. The usefulness 
of this finding as a diagnostic test for coronary artery disease 
cannot be defined from this investigation. These patients were 
carefully chosen for inclusion in this protocol, all having transient 
myocardial ischemia documented by their typical anginal symptoms, 
lactate abnormality, and electrocardiographic changes. The release 
of prostaglandin F does appear to be a specific event occurring 
during myocardial ischemia. It was not shown at heart rates 
unaccompanied by chest pain or significant ST segment depression in 
two of these patients, nor in control patients with angiographically 
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normal coronary arteries subjected to the same pacing protocol. 
All patients in this study received diazepam and atropine, 
and 5 also were receiving propranolol. Although these agents 
conceivably could affect prostaglandin metabolism, neither pro¬ 
pranolol nor atropine have been found to alter the hemodynamic 
response to prostaglandins (21,23). Furthermore, the lack of 
prostaglandin release in the normal control patients casts doubt 
on any direct effect of diazepam or atropine on prostaglandin 
release. 
The levels of prostaglandins found in this study are comparable, 
although not identical, to those previously reported for radio¬ 
immunoassay (79). Others have presented venous concentrations, 
which are not necessarily interchangeable with either coronary sinus 
or aortic levels. In general, the radioimmunoassay technique yields 
prostaglandin levels higher than those observed using mass spectro¬ 
scopy (54). This has been noted frequently, but the reasons for the 
difference are not readily apparent at this time. 
In the present investigation, prostaglandin F release was the 
dominant finding during ischemia. However, the previous studies 
(I and II) demonstrated comparable release of prostaglandins E and 
F during acute coronary occlusion in the closed-chest dog. The 
fact that prostaglandin F release during ischemia in man was more 
pronounced than prostaglandin E release may reflect a species 
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difference relative to the animal study or to the more severe 
impact of acute coronary occlusion in the experimental preparation. 
The lack of a correlation between prostaglandin F release 
and lactate production is not surprising. Lactate is supplied to 
the myocardium as a substrate in arterial blood, extracted by 
normal myocardium, and produced by the myocardium in the presence 
of ischemia and anaerobic metabolism. The net result is an alge¬ 
braic summation producing the aorto-venous difference (69). The 
kinetics of lactate uptake and release are modified by coronary 
blood flow, which was not measured in this study. Lactate pro¬ 
duction or decreased extraction, however, have been considered 
reliable indicators of regional myocardial ischemia, especially 
if considered together with ST segment depression and anginal 
pain (71). Prostaglandin F, on the other hand, is present only 
in minimal amounts in arterial blood and probably does not serve 
a systemic role. 
The significance of the demonstrated release of prostaglandins 
from the heart was examined in the experiments (IV) with indo- 
methacin, a potent inhibitor of prostaglandin synthetase (Fig 2). 
Indomethacin treatment during coronary occlusion resulted in 
immediate deleterious effects. Epicardial ST segment elevation, 
an indicator of myocardial ischemia increased, and regional 
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myocardial blood flow decreased. These directional changes 
suggest that endogenous cardiac prostaglandins play a beneficial 
role during myocardial ischemia. 
The dose of indomethacin used has been shown to completely 
block prostaglandin synthesis in all tissues studied (37-39). 
However, nonspecific actions of indomethacin on the heart (15), 
independent of its effects on prostaglandin biosynthesis, cannot 
be excluded from interpretation of these results. Similar studies 
using other inhibitors (Fig 2) are presently underway. In addition, 
confirmation of indomethacin's inhibition of cardiac prostaglandin 
release is being performed in this laboratory. 
There are some potential problems in the use of epicardial 
ST segment mapping to quantify myocardial ischemia. The electro- 
physiologic basis of ST segment elevation is poorly understood; 
it appears to depend upon variables, such as arterial oxygen 
tension, ventricular conduction, sympathetic stimulation, and 
multiple vectors determined by the distribution of ischemia (80,81). 
A linear correlation between ST segment changes and regional myo¬ 
cardial blood flow has not been established (82). Nevertheless, a 
good relationship has been found between ST segment elevation and 
subsequent evolution of myocardial necrosis (83). 
The principal defect of the microsphere technique for measuring 
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regional myocardial blood flow is non-randomicity of distribution 
of the microspheres, leading to variable measurements even in 
normal myocardium. Estimates of the error of this technique have 
ranged from 10 to 14% (84). 
Errors are maximal in the zones of severe ischemia, since 
fewer microspheres reach these zones, leading to poorer statistics 
for isotope counting. However, the number of microspheres utilized 
for this study is at the upper range of those shown to be free of 
effects on myocardial contractility. Thus, even in poorly perfused 
zones of myocardium, microsphere delivery should be adequate. 
The balance between oxygen demand and oxygen supply is 
depicted in Fig 21. When demand exceeds supply and this equality 
no longer exists, ischemia and its manifestations result (85). 
The major determinants of oxygen consumption are the contractile 
state of the heart, the heart rate, and the intraventricular wall 
tension, which is dependent upon left ventricular volume and arterial 
blood pressure. In terms of oxygen supply, aortic perfusion pressure 
and coronary vascular resistance determine coronary blood flow. 
The transmural distribution of flow (endocardial and epicardial), 
as well as total flow, are of importance in providing oxygen to the 
myocardium, especially because the subendocardial layers of the 
wall are most susceptible to ischemia. These factors, combined 
-61- 
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Figure 21. Systems diagram showing the balance between myocardial 
oxygen supply and demand. The consequences of ischemia are shown 
below. Release of vasoactive substances may lead to a negative 
feed back loop primarily affecting coronary vascular resistance. 
(From Ross, reference 65 )• 
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with the oxygen-carrying capacity of the blood, ultimately 
determine oxygen supply. 
In the normal circulation, coronary blood flow varies to 
meet myocardial oxygen demands. If local coronary flow fails to 
adjust to increased oxygen requirements, ischemia results (86). 
The processes by which local coronary flow is regulated have been 
studied by examining the coronary sinus effluent for substances 
which may modulate the coronary vascular response to myocardial 
ischemia. Lactate (70,71) and potassium (87) have been shown to 
be released from the myocardium during ischemia. The vasoactive 
compound, adenosine (88), and components of the kallikrein system 
(bradykinin) (89) also have been identified in coronary venous 
blood in man. 
Referring to Fig 21, there are several important possible 
feed back loops. For example, vasoactive compounds, such as those 
mentioned above or prostaglandins, may act to reduce coronary 
vascular resistance after release and thus diminish ischemia; 
this represents a beneficial negative loop. In contrast, left 
ventricular dysfunction may initiate a positive loop that would 
make the system more unstable. As cardiac performance decreases, 
ventricular volume, wall tension, and oxygen demands all increase; 
aortic pressure falls concomitantly, resulting in decreased coronary 
blood flow. 
-63- 

The association between cardiac prostaglandin release and 
regional myocardial ischemia in animals and man suggests that 
this pharmacologically potent substance may also play a physiologic 
role in the cardiac response to ischemia. However, it should be 
recognized that the presence of prostaglandin release in this 
pathophysiologic circumstance does not confirm a causal relationship. 
Prostaglandins may arise from myocardial cells as a direct response 
to ischemia or from coronary vascular smooth muscle cells as they 
become involved in compensatory vasodilitation. In contrast, these 
compounds could initiate a compensatory hemodynamic or metabolic 
response after release. Definition of the precise mechanisms 
involved will require further study. 
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SUMMARY 
The physiologic role of cardiac prostaglandin release 
during myocardial ischemia was evaluated in four studies. 
In 7 closed chest dogs, aortic and coronary sinus blood 
samples were obtained before, and at intervals after, balloon 
occlusion of the left anterior descending coronary artery (I). 
Samples were assayed for prostaglandins F, E and A by radio¬ 
immunoassay. All 7 animals demonstrated prostaglandin F release. 
Mean + SE post-occlusion aortic prostaglandin levels were 0.26 + 
0.1 ng/ml, while coronary sinus levels averaged 0.67 + 0.1 ng/ml 
(p < 0.001). In 6 of 7 animals, prostaglandin E also was released. 
Mean post-occlusion aortic levels were 0.24 + 0.01 ng/ml, coronary 
sinus 0.44 + 0.01 ng/ml (p < 0.001). There was no release of 
prostaglandin A. Release of prostaglandins E and F occurred 
within 10 min of occlusion in all animals and persisted until the 
animal died. 
To examine the site of prostaglandin release, simultaneous 
samples from aorta, coronary sinus, and great cardiac vein were 
obtained before and after balloon occlusion of the left circumflex 
coronary artery in 6 additional studies (II). During left cir¬ 
cumflex occlusion, the great cardiac vein drains effluent from 
normal (non-ischemic) myocardium, whereas coronary sinus drainage 
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includes blood from both ischemic and non-ischemic zones. 
All 6 animals demonstrated release of prostaglandin F 
from the ischemic region. Mean post-occlusion aortic prostaglandin 
F was 0.32 + 0.01 ng/ml. Coronary sinus prostaglandin F was 
significantly elevated at 1.69 + 0.03 ng/ml (p < 0.001), while 
the great cardiac vein level remained at 0.34+0.01 ng/ml (p > 
0.05). Prostaglandin E was released from both ischemic and non¬ 
ischemic regions. Mean aortic prostaglandin E was 0.21 + 0.01 
ng/ml, great cardiac vein 0.55 + 0.02 ng/ml (p < 0.001), and 
coronary sinus 1.07 + 0.04 ng/ml (p < 0.001). 
The relationship between myocardial prostaglandin release 
and myocardial ischemia was studied in 12 selected patients with 
multivessel coronary artery disease (III). These 12 were chosen 
for analysis because they developed angina, ischemic electro¬ 
cardiographic changes, and decreased myocardial lactate uptake 
during atrial pacing. Simultaneous aortic and coronary sinus 
blood samples were obtained at rest, during angina, and after 
recovery and were assayed for prostaglandins F, E and A by radio¬ 
immunoassay. Cardiac release of prostaglandin F was observed 
during angina in 11 of 12 patients. Aortic prostaglandin levels 
remained constant throughout each study. During angina, the 
mean + SE aorto-venous difference for prostaglandin F was -0.30 + 
-66- 
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0.04 ng/ml (p < 0.001); for prostaglandin E, -0.10 + 0.03 ng/ml 
(p < 0.001). There was no significant release of prostaglandin 
A. Samples were also drawn at sub-anginal heart rates in two 
patients. Prostaglandin F was release only during angina. In 
three control patients with a chest pain syndrome and normal 
coronary arteries, comparable atrial pacing produced no release 
of prostaglandins F, E or A. 
Epicardial ST segment maps and regional myocardial blood 
flow, determined by 15 micron microspheres, were measured in 19 
open-chest dogs 30, 60 and 75 min after left anterior descending 
coronary occlusion (IV). Biopsies from the region of the left anterior 
descending coronary artery with myocardial blood flow less than 30 
ml/lOOg/min at 30 min defined the zone of severe ischemia; biopsies with 
myocardial blood flow between 30 and 60 defined the zone of moderate 
ischemia. Biopsies from the circumflex region defined the normal zone. 
At 35 min, 10 dogs received indomethacin (10 mg/kg, iv) and 9 controls 
received saline, the indomethacin vehicle. 
Indomethacin did not affect heart rate, mean arterial blood 
pressure, or myocardial blood flow in the normal zone. In contrast, 
Indomethacin decreased myocardial blood flow in both the severely 
and moderately ischemic zones (p < 0.05). This was associated with 
a marked increase in the number of epicardial sites with ST segment 
-67- 
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elevation greater than 2 mm (p < 0.001) and the mean ST segment 
elevation (p < 0.025). 
These results, together with the known physiologic and 
pharmacologic actions of prostaglandins E and F, suggest that 
their local availability to different myocardial regions is of 
importance in the cardiac response to ischemia. 
-68- 
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